Key facts
- This page summarizes Chris Wolfe's Form 4 filing for DA32 Life Science Tech Acquisition Corp..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Aug 2021, 20:44.
Chris Wolfe - 05 Aug 2021 Form 4 Insider Report for DA32 Life Science Tech Acquisition Corp.
- Form type
- 4
- Accepted by SEC
- 09 Aug 2021, 20:44:48 UTC
- Previous filing
- 27 Jul 2021
- Next filing
- 04 Mar 2025
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Henrikki Harsu, Attorney-in-Fact for Chris Wolfe
SEC evidence
5 source fields
Reporting owner
1 detail
Key filing fact
Chris Wolfe filed Form 4 for DA32 Life Science Tech Acquisition Corp. on 09 Aug 2021.
Change
- Previous filing in this sequence was filed on 27 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DALS
transaction
Derivative
Class B Common Stock, par value $0.0001 per share
Disposed to Issuer
- Transaction value
- $0
- Shares
- -18,750
- Change %
- -13%
- Price
- $0.000000
- Shares after
- 125,000
- Date
- 05 Aug 2021
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 18,750
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares of Class B Common Stock are convertible into shares of the Issuer's Class A Common Stock as described under the heading "Description of Shares" in the Issuer's Registration Statement on Form S-1 (File No. 333-257679) (the "Registration Statement") and have no expiration date.
Footnote F2
On August 5, 2021, the Reporting Person forfeited 18,750 shares of Class B Common Stock to the Issuer for no consideration, which was exempted pursuant to Rule 16b-3(e) under the Securities Exchange Act of 1934, as amended, in connection with the underwriters' election to forfeit their overallotment option on August 4, 2021. The forfeiture was not within the Reporting Person's control as it occurred exclusively due to the underwriters' decision not to exercise the overallotment option and occurred shortly after the Issuer filed the final statutory prospectus for the initial public offering (the "IPO") disclosing all material information about the Issuer and the IPO.
SEC remarks
Henrikki Harsu, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on July 27, 2021 by Chris Wolfe.